Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/eilean-therapeutics-receives-clearance-to-initiate-rr-aml-trial-with-lomonitinib-a-selective-pan-flt3irak4-inhibitor-302108790.html
https://www.prnewswire.com/news-releases/expert-systems-expands-partnership-with-eilean-therapeutics-and-joins-its-best-in-class-ptpn2-inhibitor-program-302087090.html
https://www.prnewswire.com/news-releases/eilean-therapeutics-approved-to-initiate-first-patient-trial-with-balamenib-ze63-0302-a-selective-best-in-class-menin-inhibitor-302085538.html
https://www.prnewswire.com/news-releases/eilean-therapeutics-initiates-first-in-human-trial-with-eiletoclax-a-selective-bcl2-inhibitor-with-limited-immune-suppression-and-improved-safety-compared-to-venetoclax-and-venetoclax-like-molecules-302047277.html
https://www.prnewswire.com/news-releases/eilean-therapeutics-completes-single-dose-studies-and-initiates-multiple-dosing-of-healthy-volunteers-with-lomonitinib-a-selective-pan-flt3irak4-inhibitor-302046981.html
https://www.prnewswire.com/news-releases/eilean-therapeutics-doses-first-patient-with-ze46-0134-a-selective-flt3wt-sparing-pan-flt3mut-inhibitor-301905148.html